Human and veterinary antibiotics used in Portugal-A ranking for ecosurveillance

Toxics

Volumn 2, Issue 2, 2014, Pages 188-225

  Almeida, Anabela ^a,b   Duarte, Sofia ^a,c   Nunes, Ricardo ^d   Rocha, Humberto ^a   Pena, Angelina ^c   Meisel, Leonor ^d,e  

^a University School Vasco da Gama   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d INFARMED)   (Portugal)

^e RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Antibiotics; Consumption; Ecosurveillance; Environmental occurrence; Human medicine; Pharmacokinetic features; Portugal; Risk ranking; Veterinary medicine

Indexed keywords

EID: 84922485865     PISSN: None     EISSN: 23056304     Source Type: Journal    
DOI: 10.3390/toxics2020188     Document Type: Article

References (134)

1. Neu, H.C.; Gootz, T.D. Medical Microbiology; 4th ed.; Samuel Baron: University of Texas Medical Branch at Galveston, TX. USA, 1996; Chapter 11. Available online: http://www.ncbi.nlm.nih.gov/books/NBK7986/(accessed on 1 April 2014).
2. Aminov, R.I. A brief history of the antibiotic era: Lessons learned and challenges for the future. Front. Microbiol. 2010, 1, 1-7.
3. Alanis, A.J. Resistance to antibiotics: Are we in the post-antibiotic era? Arch. Med. Res. 2005, 36, 697-705.
4. Kalghatgi, S.; Spina, C.S.; Costello, J.C.; Liesa, M.; Morones-Ramirez, J.R.; Slomovic, S.; Molina, A.; Shirihai, O.S.; Collins, J.J. Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells. Sci. Transl. Med. 2013, 192, 192-85.
5. Seifrtová, M.; Nováková, L.; Lino, C.; Pena, A.; Solich, P. An overview of analytical methodologies for the determination of antibiotics in environmental waters. Anal. Chim. Acta 2009, 649, 158-179.
6. Ding, C.; He, J. Effect of antibiotics in the environment on microbial populations. Appl. Microbiol. Biotechnol. 2010, 87, 925-941.
7. Iglesias, A.; Nebot, C.; Miranda, J.M.; Vázquez, B.I.; Abuín, C.M.F.; Cepeda, A. Determination of the Presence of Three Antimicrobials in Surface Water Collected from Urban and Rural Areas. Antibiotics 2013, 2, 46-57.
8. Sukul, P.; Spiteller, M. Fluoroquinolone Antibiotics in the Environment. Rev. Environ. Contam. Toxicol. 2007, 191, 131-162.
9. Meisel, M.L.; Costa, M.C.; Pena, A. Regulatory approach on environmental risk assessment. Risk management recommendations, reasonable and prudent alternatives. Ecotoxicology 2009, 18, 1176-1181.
10. Boxall, A.B.A.; Fogg, L.; Blackwell, P.A.; Kay, P.; Pemberton, E.J. Review of Veterinary Medicines in the Environment. Available online: http://www.environment-agency.gov.uk (accessed on 1 April 2014).
11. Kemper, N. Veterinary antibiotics in the aquatic and terrestrial environment. Ecol. Indic. 2008, 8, 1-13.
12. De Garcia, S.O.; Pinto, P.P.; Encina, P.G.; Mata, R.I. Consumption and occurrence of pharmaceutical and personal care products in the aquatic environment in Spain. Sci. Total Environ. 2013, 444, 451-465.
13. Lindberg, R. Determination of Antibiotics in the Swedish Environment with Emphasis on Sewage Treatment Plants. Ph. D. Thesis, Umeå University, Umeå, Sweden, 2006.
14. Silva, L.J.G.; Lino, C.M.; Meisel, L.; Barceló, D.; Pena, A. Ecopharmacovigilance. In The Handbook of Environmental Chemistry, 1st ed.; Barcelo, D., Ed.; Springer-Verlag: Berlin, Germany; Heidelberg GmbH & Co. KG: New York, NY, USA, 2012; pp. 213-242.
15. EC. Regulation (EU) NO 1235/2010 (3) of the European Parliament and of the council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. Off. J. Eur. Union 2010, L348, 1-16.
16. Moulin, G.; Cavalié, P.; Pellanne, I; Chevance, A.; Laval, A.; Millemann, Y.; Colin, P.; Chauvin, C. A comparison of antimicrobial usage in human and veterinary medicine in France from 1999 to 2005. J. Antimicrob. Chemother. 2008, 62, 617-625.
17. Roos, V.; Gunnarsson, L.; Fick, J.; Larsson, D.G.; Rudén, C. Prioritising pharmaceuticals for environmental risk assessment. Sci. Total Environ. 2012, 421-422, 102-110.
18. De Souza, S.M.; Vasconcelos, E.C.; Dziedzic, M.; de Oliveira, C.M. Environmental risk assessment of antibiotics: An intensive care unit analysis. Chemosphere 2009, 7, 962-967.
19. Direcção Geral de Veterinária (DGV). Relatório Nacional de Monitorização do Consumo de Antimicrobianos; DGV: Lisboa, Portugal, 2010.
20. Direcção Geral de Veterinária (DGV). Relatório Nacional de Monitorização do Consumo de Antimicrobianos; DGV: Lisboa, Portugal, 2011.
21. European Medicines agency (EMA). Revised ESVAC Reflection Paper on Collecting Data on Consumption of Antimicrobial Agents Per Animal Species, on Technical Units of Measurement and Indicators for Reporting Consumption of Antimicrobial Agents in Animals; EMA/286416/2012-Rev.1. Veterinary Medicines Division: London, UK, 2013.
22. Medicines Statistics Reports; Market Monitorisation; 2010-2011, Infarmed-Portugal.
23. Besse, J.P.; Kausch C.B.; Garric, J. Exposure Assessment of Pharmaceuticals and Their Metabolites in the Aquatic Environment: Application to the French Situation and Preliminary Prioritization. J. Hum. Ecol. Risk Assess. 2008, 4, 665-695.
24. Infomed-Data Base for Human Medicinal Products. Available online: http://www.infarmed.pt/infomed/inicio.php (accessed on 1 April 2014).
25. Apifarma symposium-Data Base for Veterinary Medicinal Products. Available online: https://www.apifarma.pt/simposiumvet/Paginas/Pesquisaavancada.aspx (accessed on 1 April 2014).
26. European Medicines Agency (EMA). European Public MRL Assessment Report (EPMAR)-Neomycin (Including Framyacetin) (All Producing Species); Committee for Medicinal Products for Veterinary Use: Cannary Wharf, London, UK, 2013.
27. European Medicines Agency (EMA). Committee for Medicinal Products for Veterinary Use. Aminosidine Summary Report; Committee for Veterinary Medicinal Products/The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1996.
28. Rice, E.W.; Messer, J.W.; Johnson, C.H.; Reasoner D.J. Occurrence of High-Level Aminoglycoside Resistance in Environmental Isolates of Enterococci. Appl. Environ. Microbiol. 1995, 61, 374-376.
29. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products. Florfenicol (extension to pigs)-Summary Report (4); Committee for Veterinary Medicinal Products/The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1999.
30. European Medicines Agency (EMA). Florfenicol summary report (1). Committee for Veterinary Medicinal Products/The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014274.pdf (accessed on 26 February 2014).
31. Shen, J.; Wu, X.; Hu, D.; Jiang, H. Pharmacokinetics of florfenicol in healthy and Escherichia coli-infected broiler chickens. Res. Vet. Sci. 2002, 73, 137-140.
32. Liu, J.; Fung, K.F.; Chen, Z.; Zeng, Z.; Zhang, J. Pharmacokinetics of florfenicol in healthy pigs and in pigs experimentally infected with Actinobacillus pleuropneumoniae. Antimicrob. Agents Chemother. 2003, 47, 820-823.
33. Environmental Assessment for the Use of Nuflor® Injectable Solution in Cattle. 1996. Available online: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-av-gen/documents/document/ucm072358.pdf (accessed on 15 February 2014).
34. Subbiah, M.; Mitchell, S.M.; Ullman, J.L.; Call, D.R. ß-Lactams and Florfenicol Antibiotics Remain Bioactive in Soils while Ciprofloxacin, Neomycin, and Tetracycline Are Neutralized. Appl. Environ. Microbiol. 2011, 77, 7255-7260.
35. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products/The European Agency for the Evaluation of Medicinal Products; Ceftiofur-Summary Report. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_ Limits__Report/2009/11/WC500011904.pdf (accessed on 14 February 2014).
36. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Cefquinome-Summary Report (Extension to Pigs); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1999.
37. Christian, T.; Schneider, R.J.; Färber, H.A.; Skutlarek, D.; Meyer, M.T.; Goldbach, H.E. Determination of antibiotic residues in manure, soil, and surface waters. Acta Hydrochim. Hydrobiol. 2003, 31, 36-44.
38. Kuemmerer, K. Resistance in the environment. J. Antimicrob. Chemother. 2004, 54, 311-320.
39. Jiang, M.; Wang, L.; Ji, R. Biotic and abiotic degradation of four cephalosporin antibiotics in a lake surface water and sediment. Chemosphere 2010, 80, 1399-1405.
40. Gilbertson, T.J.; Hornish, R.E.; Jaglan, P.S.; Koshy, K.T.; Nappier, J.L.; Stahl, G.L.; Cazers A.R.; Nappier, J.M.; Marc, F.; Kubicek, M.F. Environmental fate of ceftiofur sodium, a cephalosporin antibiotic. Role of animal excreta in its decomposition. J. Agric. Food Chem. 1990, 38, 890-894.
41. Wang, P.; Yuan, T.; Hu, J.; Tan, Y. Determination of cephalosporin antibiotics in water samples by optimised solid phase extraction and high performance liquid chromatography with ultraviolet detector. Int. J. Environ. Anal. Chem. 2011, 91, 1267-1281.
42. Papich, M.G.; Riviere, J.E. Chloramphenicol and derivatives, macrolides, lincosamides and miscellaneous antimicrobials. In Veterinary Pharmacology and Therapeutics; 8th ed; Adams, H.R., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 868-897.
43. Chambers, H.F. Antimicrobial agents. In Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J.G., Limbird, L.E., Eds.; McGraw-Hill: New York, NY, USA, 2001; pp. 1239-1271.
44. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Erythomycin-Summary Report (2); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 2000.
45. Kowalski C.; Rolinski Z.; Zan R.; Wawron W. Pharmacokinetics of tylosin in broiler chickens. Pol. J. Vet. Sci. 2002, 5, 127-130.
46. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Tylosin-Summary Report (3); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1997.
47. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Tilmicosin-(Extension to Chicken) Summary Report (2); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1997.
48. Schluesener, M.P.; Bester, K. Persistence of antibiotics such as macrolides, tiamulin and salinomycin in soil. Environ. Pollut. 2006, 143, 565-571.
49. Zhou, Z.; Raskin, L.; Zilles, J.L. Effects of Swine Manure on Macrolide, Lincosamide, and Streptogramin B Antimicrobial Resistance in Soils. Appl. Environ. Microbiol. 2010, 76, 2218-2224.
50. Aust, M-O.; Godlinski, F.; Travis, G.R.; Hao, X.; McAllister, T.A.; Leinweber, P.; Thiele-Bruhn, S. Distribution of sulfamethazine, chlortetracycline and tylosin in manure and soil of Canadian feedlots after subtherapeutic use in cattle. Environ. Pollut. 2008, 156, 1243-1251.
51. Tong, L.; Eichhorn, P.; Pérez, S.; Wanga, X.; Barceló, D. Photodegradation of azithromycin in various aqueous systems under simulated and natural solar radiation: Kinetics and identification of photoproducts. Chemosphere 2011, 83, 340-348.
52. Vione, D.; Feitosa-Felizzola, J.; Minero, C.; Chiron, S. Phototransformation of selected human-used macrolides in surface water: Kinetics, model predictions and degradation pathways. Water Res. 2009, 43, 1959-1967.
53. Göbel, A.; McArdell, C.S.; Joss, A.; Siegrist, H.; Giger W. Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. Sci. Total Environ. 2007, 372, 361-371.
54. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Lincomycin-Summary Report (1); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK. 1998.
55. Guiguère, S. Lincosamides, pleuromutilins and, Streptogramins. In Antimicrobial Therapy in Veterinary Medicine; 4th ed.; Giguère, S., Prescott, J.F., Baggot, J.D., Walker, R.D., Dowling P.M., Eds.; Blackwell Publishing: Ames, IA, USA, 2006; pp. 179-190.
56. Wang, C.; Teppen, B.J.; Boyd, S.A.; Li, H. Sorption of Lincomycin at Low Concentrations from Water by Soils. Soil Sci. Soc. Am. J. 2012, 76, 1222-1228.
57. Chenxi, W.; Alison, L.; Spongberg, A.L.; Witter, J.D. Determination of the persistence of pharmaceuticals in biosolids using liquid-chromatography tandem mass spectrometry. Chemosphere 2008, 73, 511-518.
58. Vaden, S.L.; Riviere, J.E. Penicillin and related B-lactam antibiotics. In Veterinary Pharmacology and Therapeutics; 8th Ed; Adams, H.R., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 818-827.
59. Reyns, T.; De Boever, S.; Schauvliege, S.; Gasthuys, F.; Meissonnier, G.; Oswald, I.; de Backer, P.; Croubels, S. Influence of administration route on the biotransformation of amoxicillin in the pig. J. Vet. Pharmacol. Ther. 2008, 32, 241-248.
60. Anadon, A.; Martínez-Larranaga, M.R. Residues of antimicrobial drugs and feed additives in animal products: Regulatory aspects. Livest. Prod. Sci. 1999, 59, 183-198.
61. Li, M.; Anderson, G.D.; Phillips, B.R.; Kong, W.; Shen, D.D.; Wang, J. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab. Dispos. 2006, 34, 547-555.
62. European Medicines Agency (EMA). Reflection Paper on Use of Pleuromutilins in Food-Producing Animals in the European Union: Development of Resistance and Impact on Human and Animal Health; Committee for Veterinary Medicinal Products/The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 2012.
63. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Tiamulin-Summary Report (2) (Extension to Rabbits); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 2000.
64. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Tiamulin-Summary Report (1); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1999.
65. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Tiamulin-Summary Report (3); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 2008.
66. European Medicines Agency (EMA). Committee for Medicinal Products for Veterinary Use. European Public MRL Assessment Report (EPMAR)-Valnemulin (rabbits); 2010. [EMA/CVMP/137196/2009].
67. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Valnemulin-Summary Report (1); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1998.
68. Valnemulin-Summary of Product Characteristics. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/veterinary/medicines/000042/vet_med_000116.jsp&mid=WC0b01ac058008d7a8 (accessed on 28 February 2014).
69. Abdelraouf, K; He, J.; Ledesma, K.R.; Hu, M.; Tam, V.H. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob. Agents Chemother. 2012, 56, 5724-5727.
70. European Medicines Agency (EMA). Use of Colistin Products in Animals within the European Union: Development of Resistance and Possible Impact on Human and Animal Health; The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 2013.
71. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Colistin-Summary Report; The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1995.
72. Ahaduzzaman, Md.; Hassan, M.M.; Alam, M.; Islam, S.K.M.A.; Uddin, I. Antimicrobial Resistance Pattern against Staphylococcus aureus in Environmental Effluents. Res. J. Vet. Pract. 2014, 2, 13-16.
73. Sousa, J.; Alves, G.; Fortuna, A.; Falcão, A. Third-and Fourth-generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles. Curr. Drug Saf. 2014, doi:10.2174/1574886308666140106154754.
74. Aminimanizani, A.; Beringer, P.; Jelliffe, R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. 2001, 40, 169-187.
75. Zhanel, G.G.; Noreddin, A.M. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: Focus on respiratory infections. Curr. Opin. Pharmacol. 2001, 1, 459-463.
76. Immanuel, C.; Hemanthkumar, A.K.; Gurumurthy, P.; Venkatesan, P. Dose related pharmacokinetics of ofloxacin in healthy volunteers. Int. J. Tuberc. Lung Dis. 2002, 6, 1017-1022.
77. Slana, M.; Dolenc, M.S. Environmental Risk Assessment of antimicrobials applied in veterinary medicine-A field study and laboratory approach. Environ. Toxicol. Pharmacol. 2013, 35, 131-141.
78. Jerker, F.; Soedersrtroem, H.; Linderberg, R.H.; Phan, C.; Tysklind, M.; Larsson, D.G.J. Contamination of surface, ground, and drinking water from pharmaceutical production. Environ. Toxicol. Chem. 2009, 28, 2522-2527.
79. Dorival-García, N.; Zafra-Gómez, A.; Navalón, A.; González-López, J.; Hontoria, E.; Vílchez, J.L. Removal and degradation characteristics of quinolone antibiotics in laboratory-scale activated sludge reactors under aerobic, nitrifying and anoxic conditions. J. Environ. Manag. 2013, 120, 75-83.
80. Raju, B.; Ramesh, M.; Srinivas, R.; Raju, S.S.; Venkateswarlu, Y. Removal and degradation characteristics of quinolone antibiotics in laboratory-scale activated sludge reactors under aerobic, nitrifying and anoxic conditions. Identification and characterization of stressed degradation products of prulifloxacin using LC-ESI-MS/Q-TOF, MSn experiments: Development of a validated specific stability-indicating LC-MS method. J. Pharm. Biomed. Anal. 2011, 56, 560-568.
81. Sarmah, A.K.; Meyer, M.T.; Boxall, A.B. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. Chemosphere 2006, 65, 725-759.
82. Sittig, S.; Kasteel, R.; Groeneweg, J.; Hofmann, D.; Thiele, B.; Köppchen, S.; Vereecken, H. Dynamics of transformation of the veterinary antibiotic sulfadiazine in two soils. Chemosphere 2014, 95, 470-477.
83. Baert, K.; De Baere, A.; Croubles, D.; Gasthuys, F.; De Backer, C. Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim (trimazin 30%) after oral adminstration in non-fasted young pigs. J. Vet. Pharmacol. Ther. 2001, 24, 295-298.
84. Baert, K.; De Beare, S.; Croubles, S.; De Backer, P. Pharmacokinetics and oral bioavailability of sulfadiazine and trimethoprim in broiler chickens. Vet. Res. Commun. 2003, 27, 301-309.
85. Abu-Basha, E.A.; Gehring R.; Hantash. T.M.; Al-Shunnaq, A.F.; Idkaidek, N.M. Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches (Struthio camelus). J. Vet. Pharmacol. Ther. 2009, 32, 258-263.
86. Spoo, J.W.; Riviere, J.E. Sulphonamides. In Veterinary Pharmacology and Therapeutics; 8th ed.; Adams, H.R., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 796-817.
87. Lamshöft, M.; Sukul, P.; Zühlke, S.; Spiteller, M. Metabolism of 14C-labelled and non-labelled sulfadiazine after administration to pigs. Anal. Bioanal. Chem. 2007, 388, 1733-1745.
88. Straub, J.O. An Environmental Risk Assessment for Human-Use Trimethoprim in European Surface Waters. Antibiotics 2013, 2, 115-162.
89. Göbel, A.; McArdell, C.S.; Joss, A.; Siegrist, H.; Giger, W. Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. Sci. Total Environ. 2007, 372, 361-371.
90. Zhang, Y.; Xu, J.; Zhong, Z.; Guo, C.; Li, L.; He, Y.; Fan, W.; Chen, Y. Degradation of sulfonamides antibiotics in lake water and sediment. Environ. Sci. Pollut. Res. 2013, 20, 2372-2380.
91. Baran, W.; Adamek, E.; Ziemianska, J.; Sobczak, A. Effects of the presence of sulfonamides in the environment and their influence on human health. J. Hazard. Mater. 2011, 196, 1-15.
92. Sirtori, C.; Aguera, A.; Gernjak, W.; Malato, S. Effect of water-matrix composition on trimetoprim solar photodegradation kinetics and pathways. Water Res. 2010, 44, 2735-2744.
93. Nielsen, P.; Gyrd-Hansen, N.B. Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. J. Vet. Pharmacol. Ther. 1996, 19, 305-311.
94. Anadon, A.; Martinez-Larranaga, M.R.; Diaz, M.J.; Bringas, P.; Fernandez, M.C.; Fernandez-Cruz, M.L.; Iturbe, J.; Martinez, M.A. Pharmacokinetics of doxycycline in broiler chickens. Avian Pathoogy 1994, 23, 79-90.
95. European Medicines Agency (EMA). Oxitetracycline, Tetracycline, Chlortetracycline-Summary report (1); Committee for Veterinary Medicinal Products/The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 1999.
96. Monforts, M.H.M.M. The Trigger in the Environmental Risk Assessment for (veterinary) Medicines in the European Union: A Critical Appraisal 2005; RIVM report 601500002/2005;.
97. Tolls, J. Sorption of veterinary pharmaceuticals in soils: A review. Environ. Sci. Technol. 2001, 35, 3397-3406.
98. Szatmári, I.; Barcza, T.; Koermoeczy, P.S.; Laczay, P. Ecotoxicological assessment of doxicycline in soil. J. Environ. Sci. Health Part B 2012, 47, 129-135.
99. Wu, X.; Wei, Y.; Zheng, J.; Zhao, X.; Zhong, W. The behavior of tetracyclines and their degradation products during swine manure composting. Bioresour. Technol. 2011, 102, 5924-5931.
100. European Medicines Agency (EMA). Committee for Veterinary Medicinal Products Bacitracin (Extension to Rabbits): Summary Report (3); The European Agency for the Evaluation of Medicinal Products: Cannary Wharf, London, UK, 2002.
101. Tegeder, I.; Bremer F.; Oelkers, R.; Schobel, H.; Schüttler, J.; Brune, K.; Geisslinger, G. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. J. Antimicrob. Agents Chemother. 1997, 41, 2640-2645.
102. Burkhardt, O.; Borner, K.; von der Höh, N.; Köppe, P.; Pletz, M.W.; Nord, C.E.; Lode, H. Single-and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 2002, 50, 707-712.
103. Slatter, J.G.; Stalker, K.; Feenstra, K.L.; Welshman, I.R.; Bruss, J.B.; Sams, J.P.; Johnson, M.G.; Sanders, P.E.; Hauer, M.J.; Faqerness, P.E.; et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab. Dispos. 2001, 29, 1136-1145.
104. Westphal, J.F.; Brogard, J.M.; Caro-Sampara, F.; Adloff, M.; Blicklé, J.F.; Monteil, H.; Jehl, F. Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob. Agents Chemother. 1997, 41, 1636-1640.
105. Cunha, B.A. Vancomycin revisited: A reappraisal of clinical use. Crit. Care Clin. 2008, 24, 393-420.
106. Loos, R.; Carvalho, R.; António, D.C.; Comero, S.; Locoro, G.; Tavazzi, S.; Paracchini, B.; Ghiani, M.; Lettieri, T.; Blaha, L.; et al. EU-wide monitoring survey on emerging polar organic contaminants in wastewater treatment plant effluents. Water Res. 2013, 47, 6475-6487.
107. Verlicchi, P.; Al Aukidy, M.; Galletti, A.; Petrovic, M.; Barceló, D. Hospital effluent: Investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. Sci. Total Environ. 2012, 430, 109-118.
108. Santos, L.H.M.L.M.; Gros, M.; Rodriguez-Mozaz, S.; Delerue-Matos, C.; Pena, A.; Barceló, D.; Conceição, M.B.S.M. Montenegro. Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: Identification of ecologically relevant pharmaceuticals. Sci. Total Environ. 2013, 461-462, 302-316.
109. López-Serna, R.; Jurado, A.; Vázquez-Suñé, E.; Carrera, J.; Petrovic, M.; Barceló, D. Occurrence of 95 pharmaceuticals and transformation products in urban groundwaters underlying the metropolis of Barcelona, Spain. Environ. Pollut. 2013, 174, 305-315.
110. Calamari, D.; Zuccato, E.; Castiglioni, S.; Bagnati, R.; Fanelli, R. Strategic survey of therapeutic drugs in the Rivers Po and Lambro in Northern Italy. Environ. Sci. Technol. 2003, 37, 1241-1248.
111. Al Aukidy, M.; Verlicchi, P.; Jelic, A.; Petrovic, M.; Barcelò, D. Monitoring release of pharmaceutical compounds: Occurrence and environmental risk assessment of two WWTP effluents and their receiving bodies in the Po Valley, Italy. Sci. Total Environ. 2012, 438, 15-25.
112. Weigel, S.; Kallenborn, R.; Huhnerfuss, H. Simultaneous solid-phase extraction of acidic, neutral an.d. basic pharmaceuticals from aqueous samples at ambient (neutral) pH and their determination by gas chromatography-mass spectrometry. J. Chromatogr. A 2004, 1023, 183-195.
113. Petrovic, M.; Škrbic, B.; Živancev, J.; Ferrando-Climent, L.; Barcelo, D. Determination of 81 pharmaceutical drugs by high performance liquid chromatography coupled to mass spectrometry with hybrid triple quadrupole-linear ion trap in different types of water in Serbia. Sci. Total Environ. 2014, 468-469, 415-428.
114. Gómez, M.; Petrovic, M.; Fernández-Alba, A.R.; Barceló, D. Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters. J. Chromatogr. A 2006, 1114, 224-233.
115. López-Roldán, R.; Alda, M.L.; Gros, M.; Petrovic, M.; Martín-Alonso, J.; Barceló, D. Advanced monitoring of pharmaceuticals and estrogens in the Llobregat River basin (Spain) by liquid chromatography-triple quadrupole-tandem mass spectrometry in combination with ultra-performance liquid chromatography-time of flight-mass spectrometry. Chemosphere 2010, 80, 1337-1344.
116. Salgado, R.; Marques, R.; Noronha, J.P.; Mexia, J.T.; Carvalho, G; Oehmen, A.; Reis, M.A.M. Assessing the diurnal variability of pharmaceutical and personal care products in a full-scale activated sludge plant. Environ. Pollut. 2011, 159, 2359-2367.
117. Seifrtova, M.; Pena, A.; Lino, C.M.; Solich, P. Determination of fluoroquinolone antibiotics in hospital and municipal wastewaters in Coimbra by liquid chromatography with a monolithic column and. fluorescence detection. Anal. Bioanal. Chem. 2008, 391, 799-805.
118. Pena, A.; Chmielova, D.; Lino, C.M.; Solich, P. Determination of fluorquinolone antibiotics in surface waters from Mon.d.ego River by high performance liquid chromatography using amonolithic column. J. Sep. Sci. 2007, 30, 2924-2928.
119. Lindberg, R.; Jarnheimer, P.; Olsen, B.; Johansson, M.; Tysklind, M. Determination of antibiotic substances in hospital sewage water using solid phase extraction and liquid chromatography/mass spectrometry and group analogue internal standards. Chemosphere 2004, 57, 1479-1488.
120. Sachera, F.; Langea, F.T.; Braucha, H.-J. Blankenhornb, I. Pharmaceuticals in groundwaters. Analytical methods and results of a monitoring program in Baden-Württemberg, Germany. J. Chromatogr. A 2001, 938, 199-210.
121. Golet, E.V.; Alder, A.C.; Hartmann, A.; Ternes, T.A.; Giger, W. Trace Determination of Fluoroquinolone Antibacterial Agents in Urban Wastewater by Solid-Phase Extraction and Liquid Chromatography with Fluorescence Detection. Anal. Chem. 2001, 73, 3632-3638.
122. Golet, E.M.; Alder, A.; Giger, W. Environmental Exposure and Risk Assessment of Fluoroquinolone Antibacterial Agents in Wastewater and River Water of the Glatt Valley Watershed, Switzerland. Environ. Sci. Technol. 2002, 36, 3645-3651.
123. Martínez-Carballo, E.; González-Barreiro, C.; Scharf, S.; Gans, O. Environmental monitoring study of selected veterinary antibiotics in animal manure and soils in Austria. Environ. Pollut. 2007, 148, 570-579.
124. Vulliet, E.; Cren-Olivé, C. Screening of pharmaceuticals and hormones at the regional scale, in surface and groundwaters intended to human consumption. Environ. Pollut. 2011, 159, 2929-2934.
125. Perret, D.; Gentili, A.; Marchese, S.; Greco, A.; Curini, R. Sulphonamide residues in Italian surface and drinking waters: a small scale reconnaissance. Chromatographia 2006, 63, 225-232.
126. Madureira, T.V.; Barreiro, J.C.; Rocha, M.J.; Rocha, E.; Cass, Q.B.; Tiritan, M.T. Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal). Sci. Total Environ. 2010, 408, 5513-5520.
127. Haller, M.Y.; Müller, S.R.; McArdell, C.S.; Alder, A.C.; Suter, M.J.-F. Quantification of veterinary antibiotics (sulfonamides and trimethoprim) in animal manure by liquid chromatography-mass spectrometry. J. Chromatogr. A 2002, 952, 111-120.
128. Bendz, D.; Paxéus, N.A.; Ginn, T.R.; Logec, F.J. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. J. Hazard. Mater. 2005, 122, 195-204.
129. Winckler, C.; Engels, H.; Hund-Rinke, K.; Luckow, T.; Simon, M.; Steffens, G. Verhalten von Tetracyclinen und anderen Veterinärantibiotika in Wirtschaftsdünger und Boden; UFOPLAN 20073 248, Berlin, Germany, 2003.
130. Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde). Relatório do departamento dos medicamentos veterinários 2000-2007: o medicamento veterinário-abordagem analítica; Infarmed: Lisboa, Portugal, 2007.
131. European Medicines Agency (EMA). Guideline on the Environmental Risk Assessment of Medical Products for Human Use-EMEA/CHMP/SWP/4447/00 corr 1; Veterinary Medicines Division: London, UK.
132. European Medicines Agency (EMA). Guideline on Environmental impact Assessment (EIAS) for Veterinary Medical Products-Phase I-CVMP/VICH/592/98-Final; London, UK, 2000.
133. Mompelat, S.; le bot, B.; Thomas, O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ. Int. 2009. 35, 803-814.
134. Toutain, P.L.; Bousquét-Melou, A. Bioavailability and its assessment. J. Vet. Pharmacol. Ther. 2004, 27, 455-466.